Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) FCF Margin (2017 - 2025)

Lexaria Bioscience's FCF Margin history spans 9 years, with the latest figure at 1518.68% for Q3 2025.

  • For Q3 2025, FCF Margin rose 78450.0% year-over-year to 1518.68%; the TTM value through Nov 2025 reached 1668.28%, down 34594.0%, while the annual FY2025 figure was 1483.88%, 40650.0% down from the prior year.
  • FCF Margin for Q3 2025 was 1518.68% at Lexaria Bioscience, up from 2059.74% in the prior quarter.
  • Across five years, FCF Margin topped out at 7.29% in Q2 2022 and bottomed at 21931.2% in Q4 2023.
  • The 5-year median for FCF Margin is 1295.15% (2022), against an average of 2814.29%.
  • The largest annual shift saw FCF Margin tumbled -2063605bps in 2023 before it skyrocketed 2043563bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 8708.21% in 2021, then surged by 85bps to 1295.15% in 2022, then crashed by -1593bps to 21931.2% in 2023, then soared by 93bps to 1495.57% in 2024, then decreased by -2bps to 1518.68% in 2025.
  • Per Business Quant, the three most recent readings for LEXX's FCF Margin are 1518.68% (Q3 2025), 2059.74% (Q2 2025), and 860.86% (Q1 2025).